CGEM Q4 2024 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q4 2024 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$55M

Net Income

-$48M

EPS (Diluted)

$-0.81

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$622M

Total Liabilities

$31M

Stockholders' Equity

$590M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$77,000	+100.0%
Operating Income	-$55M	-$45M	-21.0%
Net Income	-$48M	-$24M	-100.2%